---
layout: default
title: Ganirelix
parent: 僅模型預測 (L5)
nav_order: 290
evidence_level: L5
indication_count: 10
---

# Ganirelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ganirelix: From Assisted Reproduction to Hypertrichosis (Disease)

## One-Sentence Summary

Ganirelix (DrugBank DB06785) is a GnRH receptor antagonist whose established therapeutic role is suppressing premature LH surges during controlled ovarian stimulation in assisted reproduction. The TxGNN model predicts a possible effect on **Hypertrichosis (disease)**, but this ranking is currently supported by **no clinical trials and no literature** — the score reflects the model's internal pattern-matching only, and the model's own mechanistic rationale flags the biological link as weak.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in the evidence pack. Ganirelix is internationally recognised as a GnRH antagonist used in assisted reproduction (controlled ovarian stimulation); no UK/local licence record is available to confirm the approved wording |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Ganirelix is not available in this evidence pack (flagged as a High-severity data gap). Based on information embedded in the model's own repurposing rationale, Ganirelix acts as a GnRH receptor antagonist, suppressing pituitary gonadotropin (LH) release and, downstream, gonadal steroidogenesis. Its proven clinical use is in assisted reproduction, where blocking a premature LH surge protects the timing of oocyte retrieval.

Hypertrichosis (excess hair growth) is primarily driven by local follicular biology, androgen sensitivity, or genetic/developmental factors, rather than by hypothalamic-pituitary-gonadal (HPG) axis signalling. The model's own mechanistic note for this candidate is explicit on this point: it states there is no clear pathophysiological connection between hypertrichosis and the GnRH signalling axis, and that Ganirelix's action on pituitary gonadotropin release has no direct bearing on hair follicle growth regulation.

In short, this candidate should be read as a statistical association from the knowledge graph rather than a mechanistically grounded hypothesis. It is included here for completeness and transparency, not because the underlying biology is compelling — which is reflected in the L5 evidence level and Hold recommendation below.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## UK Market Information

No marketing authorisations are currently on file for Ganirelix in this dataset (market status: Not marketed; 0 licences recorded). This should be independently verified against the MHRA product database before any further action, since Ganirelix-containing products (e.g. Orgalutran) are marketed in other jurisdictions.

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate sits at the lowest evidence tier (L5) — a model score with zero supporting clinical trials or literature, and the model's own rationale identifies the mechanistic link as unsupported. Combined with a Blocking-severity gap in TFDA/MHRA warning and contraindication data, this candidate cannot proceed to any safety pre-screening stage.

**To proceed, the following is needed:**
- Confirmed original indication and MOA data from DrugBank/SmPC (currently a data gap)
- SmPC-sourced warnings and contraindications to clear the Blocking data gap before any S1 safety review
- Preclinical or mechanistic evidence connecting GnRH antagonism (or an off-target pathway) to follicular/hair-growth biology
- Independent verification of UK marketing authorisation status via the MHRA database
- If pursued further, at minimum exploratory/observational data — no clinical or literature evidence currently exists for this indication pairing
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

